Recursion Pharmaceuticals, Inc.
RXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $2 | $2 | $2 |
| - Cash | $1 | $1 | $1 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -72.9% | 29.6% | 226.9% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -471.8% | -5.5% | -48% | -183.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -2,728.6% | -772.5% | -1,239.8% | -3,665.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3,135.3% | -899.8% | -1,373.3% | -3,966% |
| EPS Diluted | -0.36 | -0.41 | -0.5 | -0.53 |
| % Growth | 12.2% | 18% | 5.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |